Olesya Rabosyuk, CAA | |
1320 Mercy Dr Nw, Canton, OH 44708-2614 | |
(330) 498-1000 | |
Not Available |
Full Name | Olesya Rabosyuk |
---|---|
Gender | Female |
Speciality | Anesthesiology Assistant |
Experience | 6 Years |
Location | 1320 Mercy Dr Nw, Canton, Ohio |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588141261 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367H00000X | Anesthesiologist Assistant | 67.000329 (Ohio) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Hospitals Medical Group Inc | 4789682493 | 1464 |
News Archive
Prevention of H1N1 influenza virus through vaccination must be our top priority if disease patterns in the northern hemisphere follow those in the southern hemisphere this fall, writes Paul Hébert, Editor-in-Chief of CMAJ (Canadian Medical Association Journal) in an editorial.
Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended March 31, 2010 (1Q10) of $1.52, ahead of management's guidance of $1.10 to $1.20. EPS for 1Q10 included earnings of approximately $0.37 per share from higher-than-anticipated favorable prior-period development of medical claims reserves as well as $0.04 per share in higher-than-projected income tax expense due to recently enacted health reform legislation. Excluding these items, 1Q10 EPS was at the top end of the company's previous guidance range.
Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.
› Verified 3 days ago
Entity Name | University Primary Care Practices Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003935339 PECOS PAC ID: 3072417534 Enrollment ID: O20031125000767 |
News Archive
Prevention of H1N1 influenza virus through vaccination must be our top priority if disease patterns in the northern hemisphere follow those in the southern hemisphere this fall, writes Paul Hébert, Editor-in-Chief of CMAJ (Canadian Medical Association Journal) in an editorial.
Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended March 31, 2010 (1Q10) of $1.52, ahead of management's guidance of $1.10 to $1.20. EPS for 1Q10 included earnings of approximately $0.37 per share from higher-than-anticipated favorable prior-period development of medical claims reserves as well as $0.04 per share in higher-than-projected income tax expense due to recently enacted health reform legislation. Excluding these items, 1Q10 EPS was at the top end of the company's previous guidance range.
Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.
› Verified 3 days ago
Entity Name | University Hospitals Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
Prevention of H1N1 influenza virus through vaccination must be our top priority if disease patterns in the northern hemisphere follow those in the southern hemisphere this fall, writes Paul Hébert, Editor-in-Chief of CMAJ (Canadian Medical Association Journal) in an editorial.
Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended March 31, 2010 (1Q10) of $1.52, ahead of management's guidance of $1.10 to $1.20. EPS for 1Q10 included earnings of approximately $0.37 per share from higher-than-anticipated favorable prior-period development of medical claims reserves as well as $0.04 per share in higher-than-projected income tax expense due to recently enacted health reform legislation. Excluding these items, 1Q10 EPS was at the top end of the company's previous guidance range.
Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.
› Verified 3 days ago
Entity Name | Ohio Anesthesia Group, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1639348113 PECOS PAC ID: 9537222138 Enrollment ID: O20090108000069 |
News Archive
Prevention of H1N1 influenza virus through vaccination must be our top priority if disease patterns in the northern hemisphere follow those in the southern hemisphere this fall, writes Paul Hébert, Editor-in-Chief of CMAJ (Canadian Medical Association Journal) in an editorial.
Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended March 31, 2010 (1Q10) of $1.52, ahead of management's guidance of $1.10 to $1.20. EPS for 1Q10 included earnings of approximately $0.37 per share from higher-than-anticipated favorable prior-period development of medical claims reserves as well as $0.04 per share in higher-than-projected income tax expense due to recently enacted health reform legislation. Excluding these items, 1Q10 EPS was at the top end of the company's previous guidance range.
Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Olesya Rabosyuk, CAA 4665 Douglas Cir Nw # 100, Canton, OH 44718-3673 Ph: (330) 499-5700 | Olesya Rabosyuk, CAA 1320 Mercy Dr Nw, Canton, OH 44708-2614 Ph: (330) 498-1000 |
News Archive
Prevention of H1N1 influenza virus through vaccination must be our top priority if disease patterns in the northern hemisphere follow those in the southern hemisphere this fall, writes Paul Hébert, Editor-in-Chief of CMAJ (Canadian Medical Association Journal) in an editorial.
Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended March 31, 2010 (1Q10) of $1.52, ahead of management's guidance of $1.10 to $1.20. EPS for 1Q10 included earnings of approximately $0.37 per share from higher-than-anticipated favorable prior-period development of medical claims reserves as well as $0.04 per share in higher-than-projected income tax expense due to recently enacted health reform legislation. Excluding these items, 1Q10 EPS was at the top end of the company's previous guidance range.
Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.
› Verified 3 days ago
Jenna Staikoff, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1320 Mercy Dr Nw, Canton, OH 44708 Phone: 330-489-1000 | |
Jonathan S Eberlein, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 4665 Douglas Cir Nw Ste 100, Canton, OH 44718 Phone: 330-499-5700 | |
Mark Tatum, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1320 Mercy Dr Nw, Canton, OH 44708 Phone: 330-489-1000 | |
Colleen R Robson, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1320 Mercy Dr Nw, Canton, OH 44708 Phone: 330-489-1111 | |
Benjamin W. Falkenberg, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 4665 Douglas Cir Nw, Suite 100, Canton, OH 44718 Phone: 330-656-3100 | |
Mrs. Leeann Jensen, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1320 Mercy Dr Nw, Canton, OH 44708 Phone: 330-489-1000 |